Summary
Latest filing:
Daphne Zohar is Chief Executive Officer of Seaport Therapeutics, Inc. (SPTX). 1 SEC Form 4 filing on record, dated 4 May 2026.
Trading pattern
InsiderAlpha's records for Daphne Zohar go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Daphne Zohar files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Partners XII, LLC - $19.80M in SPTX purchases and sales in the last 12 months
- Robert J. Hombach - $236K in SPTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Daphne Zohar?
Daphne Zohar is a corporate insider, tracked as Chief Executive Officer of Seaport Therapeutics, Inc. (SPTX). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Daphne Zohar last file a Form 4?
The only primary Form 4 on record is dated 4 May 2026.